ReviewClinical diabetes and endocrinology2016
Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface.
Review in Clinical diabetes and endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Finite Element Analysis of Extraocular Muscle and Adipose-Dominant Pathogenesis in Thyroid Eye Disease With Clinical Implications.Translational vision science & technology · 2026Article
- Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.Ophthalmology and therapy · 2024Article
- [Endocrine orbitopathy].Radiologie (Heidelberg, Germany) · 2024Review
- Thyroid-associated ophthalmopathy: the role of oxidative stress.Frontiers in endocrinology · 2024Review
- Trends in Graves' orbitopathy research in the past two decades: a bibliometric analysis.Arquivos brasileiros de oftalmologia · 2022Article
- Detection and Correlation Analysis of Serum Uric Acid in Patients with Thyroid-Associated Ophthalmopathy.Computational and mathematical methods in medicine · 2022Article
- In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy.BMC ophthalmology · 2021Article
- The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure.Journal of ophthalmology · 2021Article
- Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.Journal of endocrinological investigation · 2020Article
- Enhanced orbital adipogenesis in a mouse model of T-cell-mediated autoimmunity, zymosan A-treated SKG mice: Implications for Graves' ophthalmopathy.Scientific reports · 2020Article
- Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.PloS one · 2020Article
- Does the Epstein-Barr Virus Play a Role in the Pathogenesis of Graves' Disease?International journal of molecular sciences · 2019Article
- Altered Corneal Nerves in Chinese Thyroid-Associated Ophthalmopathy Patients Observed by In Vivo Confocal Microscopy.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.Endocrine reviews · 2019Review
- Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.Annual review of pharmacology and toxicology · 2019Review
- Assessment of tear-evaporation rate in thyroid-gland patients.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Orbital decompression surgery for the treatment of Graves' ophthalmopathy: comparison of different techniques and long-term results.International journal of ophthalmology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Thyroid-associated ophthalmopathy (TAO) is a condition associated with a wide spectrum of ocular changes, usually in the context of the autoimmune syndrome, Graves' disease. In this topical review, we attempted to provide a roadmap of the recent advances in current understanding the pathogenesis of TAO, important aspects of its clinical presentation, its impact on the ocular surface, describe the tissue abnormalities frequently encountered, and describe how TAO is managed today. We also briefly review how increased understanding of the disease should culminate in improved therapies for patients with this vexing condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.